openPR Logo
Press release

Gastroparesis Therapeutics Market Size Report 2034 | Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.

02-17-2025 06:07 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Gastroparesis Drugs Market

Gastroparesis Drugs Market

DelveInsight's "Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Takeaways from the Gastroparesis Market Report
• The total Gastroparesis prevalent cases in the 7MM were around ~7,200,000 cases in 2023 out of which the highest Gastroparesis prevalent cases were seen in the United States.
• Gastroparesis as a disease predominantly affects women, with ~68.5% of the diagnosed patients being females, while only ~31.5% of the diagnosed patients are males.
• As per the DelveInsight estimates, United States has the largest share of diagnosed Gastroparesis cases in the 7MM. These cases are expected to grow with a significant CAGR in the study period 2020-2034.
• The leading Gastroparesis Companies working in the market include Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.
• Promising Gastroparesis Pipeline Therapies in the various stages of development include Velusetrag, tadalafil, PCS12852, Naronapride, CIN-102 Dose 1, Metoclopramide Nasal Spray, and others.

Discover which therapies are expecte to grab the Gastroparesis Market Share @ Gastroparesis Market Outlook- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroparesis Overview
Gastroparesis is a medical condition that affects the normal movement of muscles in the stomach, leading to delayed emptying of food into the small intestine. This delay in digestion can cause various symptoms such as nausea, vomiting, bloating, abdominal pain, feeling full quickly, and changes in blood sugar levels. It's often caused by damage to the vagus nerve, which controls the muscles of the stomach, or by damage to the muscles themselves. It can be associated with conditions like diabetes, neurological diseases, or certain medications. Treatment usually involves dietary changes, medication to stimulate stomach emptying, and in severe cases, surgery may be necessary.

Gastroparesis Epidemiology Segmentation in the 7MM
• Gastroparesis Prevalent cases
• Gastroparesis Gender-specific Diagnosed cases
• Gastroparesis Cause-specific Diagnosed cases
• Gastroparesis Treated cases
• Gastroparesis Age-specific Diagnosed Cases
• Gastroparesis Diagnosed Prevalent cases

Download the report to understand which factors are driving Gastroparesis Epidemiology trends @ Gastroparesis Epidemiological Insights- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroparesis Market Insights
Management of Gastroparesis involves correcting fluid, electrolyte, and nutritional deficiencies, identifying and treating the cause of delayed gastric emptying (for example, diabetes mellitus), and suppressing or eliminating symptoms. Therapeutic strategies rely on dietary modification, medications that stimulate gastric motor activity, antiemetic drug therapy, and nonpharmacological measures such as endoscopic or surgical intervention or gastric electrical stimulation.

Gastroparesis Treatment Landscape
The Gastroparesis treatment is based on the severity of the symptoms of the disease. If diabetes is associated with Gastroparesis, then treatment is done by controlling blood glucose levels. The treatment of gastroparesis mainly includes nonpharmacological steps, such as dietary modification, and pharmacological measures, including medications that stimulate gastric emptying (prokinetics), medications that reduce vomiting (antiemetics), medications for controlling pain and intestinal spasms, and surgery.

To know more about Gastroparesis treatment guidelines, visit @ Gastroparesis Treatment Market Landscape- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroparesis Marketed Therapies
• GIMOTI (metoclopramide) Nasal Spray: Evoke Pharma
Metoclopramide hydrochloride, the active ingredient in GIMOTI, is a dopamine-2 receptor antagonist. GIMOTI, a dopamine antagonist/mixed 5-HT3 antagonist/5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis.

Gastroparesis Emerging Therapies
• VLY-686 (tradipitant): Vanda Pharmaceuticals
• PCS12852: Processa Pharmaceuticals

Major Gastroparesis Companies
Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.

Learn more about the FDA-approved drugs for Gastroparesis @ Drugs for Gastroparesis Treatment- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Gastroparesis Market Report
• Coverage- 7MM
• Gastroparesis Companies- Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.
• Gastroparesis Therapies- Velusetrag, tadalafil, PCS12852, Naronapride, CIN-102 Dose 1, Metoclopramide Nasal Spray, and others.
• Gastroparesis Market Dynamics: Gastroparesis Market Drivers and Barriers
• Gastroparesis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Gastroparesis Drugs in development @ Gastroparesis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of Gastroparesis
4. Gastroparesis Market Overview at a Glance
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Gastroparesis: Six Major Market Analysis
13. Unmet Needs
14. SWOT Analysis
15. KOL Views
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gastroparesis Therapeutics Market Size Report 2034 | Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others. here

News-ID: 3872232 • Views:

More Releases from DelveInsight Business Research LLP

Paroxysmal Nocturnal Hemoglobinuria Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight
Paroxysmal Nocturnal Hemoglobinuria Treatment Pipeline Shows Strong Momentum as …
DelveInsight's, "Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Haemoglobinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies …
DelveInsight's "Sarcopenia Pipeline Insight 2026" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Sarcopenia pipeline landscape. It covers the Sarcopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sarcopenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Sarcopenia Research. Learn more about
Thymidine Kinase 2 Deficiency Market is projected to grow at a CAGR of 50% by 2034, estimates DelveInsight
Thymidine Kinase 2 Deficiency Market is projected to grow at a CAGR of 50% by 20 …
DelveInsight's "Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Thymidine Kinase 2 Deficiency epidemiology, market, and clinical development understanding, Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Thymidine Kinase 2 Deficiency therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom,
Lupus Nephritis Clinical Trial Pipeline Appears Robust With 35+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Lupus Nephritis Clinical Trial Pipeline Appears Robust With 35+ Key Pharma Compa …
DelveInsight's "Lupus Nephritis Pipeline Insight 2026" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious about the latest updates

All 5 Releases


More Releases for Gastroparesis

Rising Diabetes Prevalence Ignites Momentum In Diabetic Gastroparesis Treatment …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Diabetic Gastroparesis Treatment Industry Market Size Be by 2025? The overall valuation of the diabetic gastroparesis therapy sector has demonstrated consistent upward movement lately, projected to increase from $3.89 billion in 2024 to $4.05 billion in the subsequent year, reflecting a 4.2% compounded annual growth rate;
Top Trends Transforming the Gastroparesis Drugs Market Landscape in 2025: Develo …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Gastroparesis Drugs Industry Market Size Be by 2025? The market size for drugs treating gastroparesis has significantly increased in the past few years. The progression is predicted to continue from $5.39 billion in 2024 to $5.73 billion in 2025, representing a compound annual growth rate (CAGR)
Rising Healthcare Expenditure Fuels Growth In The Gastroparesis Market: Transfor …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Gastroparesis Industry Market Size Be by 2025? In recent times, the gastroparesis market size has been witnessing a consistent growth. It is projected to advance from $6.84 billion in 2024 to $7.17 billion in 2025, registering a compound annual growth rate (CAGR) of 4.9%. Several factors
Prominent Gastroparesis Drugs Market Trend for 2025: Development Of Innovative G …
What Are the Projected Growth and Market Size Trends for the Gastroparesis Drugs Market? In recent times, the gastroparesis drugs market has experienced substantial growth. The market size is projected to expand from $5.39 billion in 2024 to $5.73 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. Various factors like the side effects associated with current treatments, research into gastrointestinal motility, clinical requirements, patient advocacy efforts and
Gastroparesis Market Size | Segmentation, Outlook, Industry Report
The Gastroparesis Market was valued at US$ 4,338.61 million in 2019 and is projected to reach US$ 6,025.11 million by 2027; it is expected to grow at a CAGR of 4.3%during 2020-2027. The growth of the market is mainly attributed to the increasing prevalence of diabetes and growing geriatric population. However, side effects of gastroparesis drugs obstruct the growth of the market. Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00024714?utm_source=OpenPr&utm_medium=10640 Analysis of the Top Market
Gastroparesis Market - Transforming lives through comprehensive gastroparesis tr …
Newark, New Castle, USA: The "Gastroparesis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Gastroparesis Market: https://www.growthplusreports.com/report/gastroparesis-market/8691 This latest report researches the industry structure, sales, revenue, price and